Loading...
Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective
BACKGROUND: In Australia, the reimbursement of botulinum neurotoxin-A (BoNT-A) on the Pharmaceutical Benefits Scheme for the treatment of moderate to severe spasticity of the upper limb following a stroke (PSS-UL) is restricted to four treatment cycles per upper limb per lifetime. This analysis exam...
Na minha lista:
| Udgivet i: | Pharmacoecon Open |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6393278/ https://ncbi.nlm.nih.gov/pubmed/29915932 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-018-0086-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|